Brittany Daggett’s Post

Unlock deals, alliances, and BD&L contacts to propel your strategic growth in oncology. Dive into insights now! Book your 30 min demo here: https://lnkd.in/d4_52kjn #cancer #oncology #cancerresearch #drugdiscovery #drugdevelopment #1stoncology #biotech #pharma #immunooncology #clinicaltrials #academic #businessdevelopment #searchandevaluation #commercialopportunities

🔬 The future of oncology testing is here! NGS is paving the way, but there are practical challenges when bringing it in clinical labs. Get answers at our virtual roundtable on Nov 12 with top NGS experts. Learn about: Considerations on choosing between panel or whole-genome/exome testing Best practices in variant analysis and interpretation And much more! Secure your spot today: https://lnkd.in/emx-idpS #NGSInOncology #CancerGenomics #NextGenSequencing #OncologyDiagnostics #ClinicalNGS

📢 Recap Our Webinar on FSP Strategic Partnerships! Missed our webinar on Implementing Gold Standard FSP Partnerships to Fuel Efficient Drug Development? Catch up on all the insights and strategies from industry experts, Elisa Mansfield, Ping-Chung Chang and Natalie Fforde here: https://lnkd.in/eYRtgQ64 #DrugDevelopment #FSP #Oncology #ClinicalTrials #WebinarRecap

🔗 Click here to access the first webinar in our series focused on our innovative technology platform for the evaluation of novel anti-cancer drugs based on the generation of patient tumor replicas in embryos (embryo patient-derived xenografts: Embryo-PDX): https://lnkd.in/exnucnPr Join our experts to learn more about how our New Approach Methodology (NAM) can efficiently assess the efficacy and elucidate the of mechanisms of action of oncology drugs. #webinar #replay #lifescience #oncology #CRO #partnering #drugdevelopment #3Rs #ethical #NAM #PDXmodel 

We're excited to share our latest whitepaper: "How Continuous Screening Can Increase Oncology Clinical Trial Enrollment." In particular, the whitepaper highlights: * Why timing is a crucial, overlooked variable in clinical trial enrollment * 3 reasons the status quo of point-in-time monitoring falls short * A step-by-step quantified breakdown of how continuous screening solutions like Triomics' Prism increase cancer trial screening

[A new approach methodology NAM for your drug discovery and development] Missed our webinar series? Don't worry! We invite you today to access the replay of our first webinar in the series: 🎥 “A unique technology platform using an innovative patient-derived xenograft model”. 🔗Click here to access: https://lnkd.in/exnucnPr This webinar is an introduction to the ERBC Group unique technology platform dedicated to the evaluation of innovative #cancer drugs. #webinar #replay #lifescience #oncology #CRO #partnering #drugdevelopment #3Rs #ethical #NAM #PDXmodel #PDX #translational

As #oncology continues to drive growth in the global pharma market, there is increasing interest in new combinations and drug modalities. Explore the trends and innovation shaping the future of #cancer care in this new blog. https://bit.ly/3UQngTJ #IQVIAMIDAS #AnalyticsLink

This piece by Ned Pagliarulo in BioPharma Dive is a great primer on our recently announced collaboration with ARTBIO and the excitement surrounding #radiopharmaceuticals overall. As Ned writes, “The radiopharma field is booming, drawing substantial investment from large companies and venture capital firms eager to capitalize on the drugs’ potential to balance cancer-killing potency with better safety.” The Helicon-enabled radioligand therapies we will co-develop will benefit from the hyper-tunability of Helicons, to control the drugs’ distribution and half-life, and from the uniqueness of lead-212, one of the most promising isotopes for radiopharmaceutical use. Check out this photo of our teams together kicking off our partnership, and read the story here: https://bit.ly/3KN2zm5 #radioligandtherapy #cancer #oncology #peptides #Helicons #patients  

In this compelling article for Applied Clinical Trials, IQVIA’s David Alsadius, Sergio Sanchez-Gambetta, and Matt Simmons discuss several exciting areas of progress in oncology R&D. Our experts outline what sponsors, clinical research organizations, regulators and other key stakeholders will need to keep in mind for successful drug development. Read their insights in full. https://bit.ly/3WGIt3t #clinicalresearch #drugdevelopment #oncology

Understand the implications of ILD toxicity monitoring in Antibody Drug Conjugate (#ADC\) trials and how to meet worldwide #regulatory expectations in this on-demand webinar. https://lnkd.in/gcagzwaS #MedicalImaging #Oncology #ChooseCalyx